Evidence map›Paper›PMID 23717629›Full record

ArticlePloS one2013

Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD).

Neal X Chen, Kraiwiporn Kiattisunthorn, Kalisha D O'Neill, Xianming Chen, Ranjani N Moorthi, Vincent H Gattone, Matthew R Allen, Sharon M Moe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  4. Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.American journal of physiology. Heart and circulatory physiology · 2015
    Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Article
  17. miRNA biomarkers in renal disease.International urology and nephrology · 2022
    Review
  18. Review
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Neal X ChenMedicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Kraiwiporn Kiattisunthorn
Kalisha D O'Neill
Xianming Chen
Ranjani N Moorthi
Vincent H Gattone
Matthew R Allen
Sharon M Moe
Indiana University School of MedicineIndiana University – Purdue University Indianapolis · USMahidol University · TH

Funding

Bisphosphonates in the treatment of chronic kidney disease-mineral bone diseaseR01AR058005 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M · 2010 to 2014
$1.6M
NIAMS NIH HHS 5R01AR058005NIAMS NIH HHS R01 AR058005
6 · The paper itself

Abstract

Patients with CKD have abnormal vascular remodeling that is a risk factor for cardiovascular disease. MicroRNAs (miRNAs) control mRNA expression intracellularly and are secreted into the circulation; three miRNAs (miR-125b, miR-145 and miR-155) are known to alter vascular smooth muscle cell (VSMC) proliferation and differentiation. We measured these vascular miRNAs in blood from 90 patients with CKD and found decreased circulating levels with progressive loss of eGFR by multivariate analyses. Expression of these vascular miRNAs miR-125b, miR-145, and miR-155 was decreased in the thoracic aorta in CKD rats compared to normal rats, with concordant changes in target genes of RUNX2, angiotensin II type I receptor (AT1R), and myocardin. Furthermore, the expression of miR-155 was negatively correlated with the quantity of calcification in the aorta, a process known to be preceded by vascular de-differentiation in these animals. We then examined the mechanisms of miRNA regulation in primary VSMC and found decreased expression of miR-125b, 145, and 155 in VSMC from rats with CKD compared to normal littermates but no alteration in DROSHA or DICER, indicating that the low levels of expression is not due to altered intracellular processing. Finally, overexpression of miR-155 in VSMC from CKD rats inhibited AT1R expression and decreased cellular proliferation supporting a direct effect of miR-155 on VSMC. In conclusion, we have found ex vivo and in vitro evidence for decreased expression of these vascular miRNA in CKD, suggesting that alterations in miRNAs may lead to the synthetic state of VSMC found in CKD. The decreased levels in the circulation may reflect decreased vascular release but more studies are needed to confirm this relationship.

Indexed as

AgedAnimalsBlood VesselsCase-Control StudiesFemaleGlomerular Filtration RateHumansKidney Failure, ChronicMaleMicroRNAsMiddle AgedRatsReal-Time Polymerase Chain ReactionMicroRNAs

Identifiers

PMID23717629
PMCPMC3661525
OpenAlexW2028187264

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.